![New antiviral pill for COVID cut hospital and death risk by 89%, Pfizer says](https://cbsnews2.cbsistatic.com/hub/i/r/2021/10/07/f530d3c6-3559-41b7-a573-f70d83e5767b/thumbnail/1200x630/53f09fceb35160a44d489428228e5860/cbsn-fusion-pfizer-asks-for-emergency-approval-for-shot-for-kids-thumbnail-809760-640x360.jpg)
New antiviral pill for COVID cut hospital and death risk by 89%, Pfizer says
CBSN
Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% as the drugmaker joins the race to bring the first easy-to-use medication against the coronavirus to the U.S. market.
Currently all COVID-19 treatments used in the U.S. require an IV or injection. Competitor Merck's COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on Thursday the United Kingdom became the first country to approve it.
Pfizer said it will ask the FDA and international regulators to authorize its pill as soon as possible, after independent experts recommended halting the company's study based on the strength of its results. Once Pfizer applies, the FDA could make a decision within weeks or months.
![](/newspic/picid-6252001-20250206120759.jpg)
Since ChatGPT was released just over two years ago, its use everywhere from the workplace to academia has expanded significantly. In schools across the country, teachers and administrators have been grappling with how to contend with this new tool. While some say it has benefits, others point out the negatives, like cheating.